Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07310784) titled 'A Phase II Trial of LM103 in Advanced Melanoma' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd.
Condition:
Advanced Melanoma
Intervention:
Biological: LM103 TILs Injection
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: December 16, 2025
Target Sample Size: 92
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07310784
Disclaimer: Curated by HT Syndic...